The history of cyclosporin A (Sandimmune®) revisited: Another point of view

Aldridge, D. C., Armstrong, J. J., Speake, R. N., and Turner, W. B., The cytochalasins, a new class of biologically active mould metabolites. Chem. Commun. (1967) 26–27.

Arrenbrecht, S., and Lazary, S., Effect of the immunosuppressive agent ovalicin on the kinetics of antibody formation. Agents and Actions1 (1970) 221–226.

Bäumler, E.: Die grossen Medikamente. Lübbe, Bergisch Gladbach 1992.

Bernard, J., Ciclosporin: Foreword. Prog. Allergy38 (1986) 1–8.

Bollinger, P., Sigg, H. P., and Weber, H. P., Die Struktur von Ovalicin. Hely. chim. Acta56 (1973) 819–830.

Borel, J. F., Comparative study of in vitro and in vivo drug effects on cell-mediated cytotoxicity. Immunology31 (1976) 631–641.

Borel, J. F., The history of cyclosporin A and its significance, in: Cyclosporin A, pp. 5–17. Ed. D. J. G. White. Elsevier, Oxford 1982.

Borel, J. F., Address at the presentation of the Prix Galien of France, published in Press Folder of Sandoz Basel, May 1984.

Borel, J. F., Interview published in the brochure “Sandimmune” of Laboratories Sandoz, France, 1984.

Borel, J. F., Feurer, C., Gubler, H. U., and Stähelin, H., Biological effects of cyclosporin A: a new antilymphocytic agent. Agents and Actions6 (1976) 468–475.

Borel, J. F., Feurer, C., Magnée, C., and Stähelin, H., Effects of the new anti-lymphocytic peptide cyclosporin A in animals. Immunology32 (1977) 1017–1025.

Borel, J. F., Kis, Z. L., The discovery and development of cyclosporine (Sandimmune). Transplant. Proc.23 (1991) 1867–1874.

Borel, J. F., Rüegger, A., and Stähelin, H., Cyclosporin A: a new antilymphocytic agent. Experientia32 (1976) 777.

Bridel, F., Ces médicaments qui ont changé la vie. Chapitre 3, pp. 26–38. Payot, Lausanne 1985.

Bueding, E., Hawkins, J. and Cha, Y.-N., Antischistosomal effects of cyclosporin A. Agents and Actions11 (1981) 380–383.

Calne, R. Y., The development of immunosuppression in organ transplantation. Progr. Transplant.1 (1984) 1–10.

Calne, R. Y., and White, D. J. G., cyclosporin A — a powerful immunosuppressant in dogs with renal allografts. IRCS med. Sci.5 (1977) 595.

Calne, R. Y., White, D. J. G., Rolles, K., Smith, D. P., and Herbertson, B. M., Prolonged survival of pig orthotopic heart grafts treated with cyclosporin A. LancetI (1978) 1183–1185.

Calne, R. Y., White, D. J. G., Thiru, S., Evans, D. B., McMaster, P., Dunn, D. C., Craddock, G. N., Pentlow, D. B., and Rolles, K., Cyclosporin A in patients receiving renal allografts from cadaver donors. LancetII (1978) 1323–1327.

Carter, S. B., Effects of cytochalasins on mammalian cells. Nature, Lond.213 (1967) 261–264.

Closse, A., und Huguenin, R., Isolierung und Strukturaufklärung von Chlamydocin. Helv. chim. Acta57 (1974) 533–545.

Dawkins, A. W., Grove, J. F., and Tidd, B. K., Diacetoxyscirpenol and some related compounds. Chem. Commun. (1965) 27–28.

DeSimone, P. A., Greco, F. A., Lessner, H. F., and Bartolucci, A., Phase II evaluation of anguidine (NSC 141537) in 5-day courses in colorectal adenocarcinoma. A Southeastern Cancer Study Group trial. Am. J. clin. Oncol.9 (1986) 187–188.

Doyle, T. W., and Bradner, W. T., Trichothecanes, in: Anticancer agents based on natural product models, pp. 43–72. Eds J. M. Cassady and J. D. Douros. Academic Press, New York 1980.

Dreyfuss, M., Neue Erkenntnisse aus dem pharmakologischen Pilz-Screening. Sydowia39 (1986) 22–36.

Dreyfuss, M., and Chapela, I. H., Potential of fungi in the discovery of novel, low-molecular weight pharmaceuticals, in: The Discovery of Natural Products with Therapeutic Potential, pp. 49–80. Ed. V. P. Gullo. Butterworth-Heinemann, Boston 1994.

Dreyfuss, M., Härri, E., Hofmann, H., Kobel, H., Pache, W., and Tscherter, H., Cyclosporin A and C. New metabolites fromTrichoderma polysporum (Link ex pers.) Rifai. Europ. J. appl. Microbiol.3 (1976) 125–133.

Editorial, Cyclosporin turns five. Science242 (1988) 198.

Flury, E., Mauli, R., and Sigg, H. P., The constitution of diacetoxyscirpenol. Chem. Commun. (1965) 26–27.

Gorner, P., Wonderworker. Chicago Tribune, Dec. 28, 1988.

Green, C. J., and Allison, A. C., Extensive prolongation of rabbit kidney allograft survival after short-term cyclosporin-A treatment. The LancetI (1978) 1182–1183.

Gutzwiller, J., and Tamm, C., Ueber die Struktur von Verrucarin A. Helv. chim. Acta48 (1965) 157–176.

Haller, M., Der Sandimmun-Krimi: Die Geschichte des Medikamentes, mit dem heute am meisten Geld verdient wird. Weltwoche (Zürich) Dec. 3 (1992) 61–63; Dec. 10 (1992) 53; Dec. 17 (1992) 47. An English translation by F. Niklaus is available from the author of the present paper.

Härri, E., Loeffler W., Sigg, H. P. Stähelin, H., Stoll, Ch., Tamm, Ch., and Wiesinger, D., Ueber die Verrucarine und Roridine, eine Gruppe von cytostatisch hochwirksamen Antibiotica aus Myrothecium-Arten. Helv. chim. Acta45 (1962) 839–853.

Härri, E., Loeffler W., Sigg, H. P., Stähelin, H., and Tamm, Ch., Ueber die Isolierung neuer Stoffwechselprodukte aus Penicillium brefeldianum Dodge. Helv. chim. Acta46 (1963) 1235–1243.

Hartmann, G. R., Richter, H., Weiner, E. M., and Zimmermann, W., On the mechanism of action of the cytostatic drug anguidine and of the immunosuppressive agent ovalicin, two sesquiterpenes from fungi. Planta med.34 (1978) 231–252.

Hofmann, A., Planung und Zufall in der pharmazeutischchemisschen Forschung. Sandoz Bulletin50 (1979) 4–17.

Kolata, G., Drug transforms transplant medicine (Editorial). Science221 (1983) 40–42.

Kostakis, A. J., White, D. J. G., and Calne, R. Y., Prolongation of the rat heart allograft survival by cyclosporin A. IRCS med. Sci.5 (1977) 280.

Lazary S., and Stähelin, H., Immunosuppressive, Wirkung von Podophyllumstoffen und andern Cytostatica, in: Proc. 5th Internat. Congr. Chemotherapy, (Vienna), pp. 317–322. Eds K. H. Spitzy and H. Haschek. Wiener mediz. Akademie. Wien 1967.

Lazary, S., and Stähelin, H., Immunosuppressive and specific antimitotic effects of ovalicin. Experientia24 (1968) 1171–1173.

Lazary, S., and Stähelin, H., Immunosuppressive effect of a new antibiotic: ovalicin. Antibiotica et Chemother.15 (1969) 177–181.

Lazary, S., and Stähelin, H., Ovalicin and other drugs in experimental allergic encephalomyelitis (EAE). Experientia26 (1970) 691.

Mirocha, C. J., Pawlowsky, R. A., Chatterjee, K., Watson, S., and Hayes, W., Analysis of Fusarium toxins in various samples implicated in biological warfare in Southeast Asia. J. Ass. off. analyt. Chem.66 (1983) 1485–1499.

Misumi, Y., Misumi, Y., Miki, K., Takatsuki, A., Tamura, G., and Ikehara, Y., Novel blockade by brefeldin A of intracellular transport of secretory proteins in cultured rat hepatocytes. J. biol. Chem.261 (1986) 11398–11403.

Pestka, J. J., and Forsell, J. H., Inhibition of human lymphocyte transformation by the macrocyclic trichothecenes roridin A and verrucarin A. Toxic. Lett.41 (1988) 215–222.

Petcher, T. J., Weber, H. P., and Rüegger., A., Crystal and molecular structure of an iodo-derivative of the cyclic undecapeptide cyclosporin A. Helv. chim. Acta59 (1976) 1480–1488.

Powles, R. L., Barrett, A. J., Clink, H., Kay, H. E. M., Sloane, J., and McElwain, T. J., Cyclosporin A for the treatment of graft-versus-host disease in man. LancetII (1978) 1327–1331.

Re, R. N., Bioburst: The Impact of Modern Biology on the Affairs of Man. Louisiana State Univ. Press, Baton Rouge 1986.

Roberts, R. M., Serendipity. Wiley, New York 1989.

Rothweiler, W., and Tamm, Ch., Isolation and structure of phomin. Experientia22 (1966) 750–752.

Rüegger, A., Kuhn, M., Lichti, H., Loosli, H. R., Huguenin, R., Quiquerez, C. and von Wartburg, A., Cyclosporin A, ein imunosuppressiv wirksamer, Peptidmetabolit ausTrichoderma polysporum (Link ex Pers.) Rifai. Helv. chim. Acta59 (1976) 1075–1092.

Rüsch, M. E., and Stähelin, H., Ueber einige biologische Wirkungen des Cytostaticum Verrucarin A. Arzneimittelforsch. (Drug Research)15 (1965) 893–897.

Sawada, S., Suzuki, G., Kawase, Y., and Takaku, F., Novel immunosuppressive agent, FK 506. In vitro effects on the cloned T cell activation. J. Immun.139 (1987) 1797–1803.

Sigg, H. P., Die Konstitution von Brefeldin A. Helv. chim. Acta47 (1964) 1401–1415.

Sigg, H. P., Mauli, R., Flury, E., and Hauser, D., Die Konstitution von Diacetoxyscirpenol. Helv. chim. Acta48 (1965) 962–988.

Sigg, H. P., and Weber, H. P., Isolierung und Strukturaufklärung von Ovalicin. Helv. chim. Acta.51 (1968) 1395–1408.

de Souza, N. J., Ganguli, B. N., and Reden, J., Strategies in the discovery of drugs from natural sources. Ann. Rep. med. Chem17 (1982) 301–310.

Stähelin, H., Ueber osmotisches Verhalten und Fusion nackter Protoplasten von Bac. anthracis. Schweiz. Zs. allg. Path. Bakt.17 (1954) 296–310.

Stähelin, H., Internal Report, Sandoz Pharma of July 13, 1959, on compound No. 9648 (phomin, cytochalasin B).

Stähelin, H., Internal Report Sandoz Pharma of October 6, 1960, on compound No. 11-247 (HPS 277, brefeldin A).

Stähelin, H., A simple quantitative test for cytostatic agents using non-adhering cells in vitro. Med. exp.7 (1962) 92–102.

Stähelin, H., Internal Report Sandoz Pharma of November 18, 1964, on compounds No. 7827 and 11-699/2.

Stähelin, H., 4′-Demethyl-epipodophyllotoxin thenylidene glucoside (VM 26), a podophyllum compound with a new mechanism of action. Europ. J. Cancer6 (1970) 303–311.

Stähelin, H., Ciclosporin: Historical background. Prog. Allergy38 (1986) 19–27.

Stähelin, H., Enhanced toxicity of the immunosuppressant ovalicin upon application to the skin. Experientia44 (1988) 611–613.

Stähelin, H., The development of immunosuppressive agents from x-rays to cyclosporin, in: Immunology 1930–1980, Essays on the History of Immunology, pp. 185–201. Ed. P. M. H. Mazumdar. Wall and Thompson, Toronto 1989.

Stähelin, H., and Cerletti, A., Experimentelle Ergebnisse mit den Podophyllum-Cytostatica SP-I und SP-G. Schweiz. med. Wschr.94 (1964) 1490–1502.

Stähelin, H., Kalberer-Rüsch, M. E., Signer, E., und Lazary, S., Ueber einige biologische Wirkungen des Cytostaticum Diacetoxyscirpenol. Arzneimittelforsch. (Drug Research)18 (1968) 989–994.

Stähelin, H., Karnovsky, M. L., Farnham, A. E., and Suter, E., Studies on the interaction between phagocytes and tubercle bacilli. III. Some metabolic effects in guinea pigs associated with infection with tubercle bacilli. J. exp. Med.105 (1957) 265–277.

Stähelin, H., and Trippmacher, A., Cytostatic activity of chlamydocin, a rapidly inactivated cyclic tetrapeptide. Europ. J. Cancer10 (1974) 801–808.

Stähelin, H., and von Wartburg, A. The chemical and biological route from podophyllotoxin glucoside to etoposide: ninth Cain Memorial Award Lecture. Cancer Res.51 (1991) 5–15.

Tamm, Ch., The antibiotic complex of the verrucarins and roridins. Fortschr. Chem. Org. Naturst.31 (1974) 63–117.

Tamura, G., Ando, K., Suzuki, S., Takatsuki, A., and Arima, K., Antiviral activity of brefeldin A and verrucarin A. J. Antibiotic.21 (1968) 160–161.

Thommen, K., Antimalarial activity of cyclosporin A. Agents and Actions11 (1981) 770–773.

Thompson, L., Jean-François Borel's transplanted dream. Washington Post, November 15, 1988.

Traxler, R., In der Pharma-Forschung beginnt die Zukunft in der Vergangenheit. Nordschweiz, September 23, 1988.

Weiner, E., Ueber die immunosuppressive Wirkung des Sesquiterpens Ovalicin auf Lymphozyten. Thesis, Univ. of Würzburg 1976.

White, D. J. G., and Calne, R. Y., The use of cyclosporin A immunosuppression in organ grafting. Immun. Rev.65 (1982) 115–131.

Wiederrecht, G., Lam E., Hung, S., Martin, M., and Sigal, N., The mechanism of action of FK-506 and cyclosporin A. Ann. N. Y. Acad. Sci.696 (1993) 9–19.

Wiskott, E., Sandimmun. Internat. Sandoz Gazette, March 1983.

Woodruff, M., Concluding Remarks, in: Cyclosporin A, pp. 569–573. Ed. D. J. G. White. Elsevier, Oxford 1982.

van Ypersele de Strihou, C., La cyclosporine. J. Pharm. Belg.40 (1985) 109–112.